Autoplaque vs Tempus ECG-AF

Autoplaque is described as workstation-based software with automated segmentation that is reviewable and editable by clinicians, suggesting a direct and interactive user experience. This hands-on control over the analysis output provides a high degree of usability for medical professionals. Tempus ECG-AF, while integrated into facility systems, focuses more on automated analysis rather than direct clinician interaction with the algorithm's output.

Both tools offer significant clinical value and are FDA-cleared. Autoplaque provides immediate, quantitative analysis of coronary plaques and stenoses from CT angiography, directly aiding in heart attack risk prediction and treatment guidance based on existing pathology. Tempus ECG-AF offers predictive insights for future AF risk, which is valuable for proactive management, but Autoplaque's direct quantitative assessment for acute decision-making provides a more immediate and comprehensive clinical impact.

Tempus ECG-AF clearly wins this dimension by providing transparent information about CMS reimbursement, with specific CPT codes and a Medicare rate of $128.90 effective January 1, 2025. This significantly enhances its value proposition for healthcare providers by offering a clear path to cost recovery. Autoplaque's pricing is not disclosed, making its financial value harder to assess.

Tempus ECG-AF demonstrates strong enterprise readiness with explicit HIPAA compliance, BAA availability, and integration into healthcare facility systems, including compatibility with major ECG vendors like GE and Philips. Autoplaque, being workstation-based and lacking specified compliance details in the provided information, appears less suited for large-scale enterprise deployment.

Both tools are innovative, but Tempus ECG-AF stands out by predicting future atrial fibrillation risk from a standard 12-lead ECG, representing a novel application of AI to extend the utility of existing diagnostic data. It is noted as the first FDA clearance for an AF indication in its category. Autoplaque's quantitative plaque analysis is also advanced but focuses on detailed assessment of existing pathology.

Tempus ECG-AF offers a more transparent and readily available support structure, with clear email and phone contacts for customer and cardiology support, and evidence of FAQs and troubleshooting resources for its products. While Autoplaque mentions user manuals and sales contacts, the direct support channels are less explicitly detailed in the available information.